FK506 nephrotoxicity

Renal Failure

Volumn 21, Issue 3-4, 1999, Pages 319-329

  Finn, William F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin; FK506; Nephrotoxicity; Tacrolimus; Transplantation

Indexed keywords

ADRENERGIC RECEPTOR; CALCINEURIN; CALCIUM; CALCIUM CHANNEL; CYTOKINE; PROSTAGLANDIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

BLOOD VESSEL INJURY; CALCIFICATION; CELL PROLIFERATION; CELL VACUOLE; CONFERENCE PAPER; CYTOKINE PRODUCTION; ENDOTHELIUM LESION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY INJURY; NEPHROTOXICITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0033023568     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229909085094     Document Type: Conference Paper

References (48)

1. Gonschior A-K, Christians U, Winkler M, Linck A, Baumann J, Sewing K-F: Tacrolimus (FK506) metabolite patterns in bood from liver and kidney transplant patients. Clin Chem 42:1426-1432, 1996.
2. Lemoine A, Azoulay D, Dennison A, Kiffel L, Pichard L, Furlan V, Bienvenu T, Fredj G, Debuire B, Maurel P, et al: FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation. Hepatology 20:1472-1477, 1994.
3. Assan R, Fredj G, Larger E, Feutren G, Bismuth H: FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete et Metabolisme 20:49-52, 1994.
4. Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Current Opinion in Nephrology & Hypertension 4:472-477, 1995
5. Wang T, Li S-L, Danielson PD, Shah PC, et al.: The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type 1 receptors. Cell 86:435-444, 1996.
6. Su O, Weber L, Le Hir M, Zenke G, Ryffel B: Nephrotoxicity of cyclosporine A and FK506: inhibition of calcineurin phosphatase. Renal Physiology & Biochemistry 18:128-139, 1995.
7. Ryffel B, Weber E, Mihatsch MJ, Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. Experimental Nephrology 2:324-333, 1994.
8. Mitamura T, Yamada A, Ishida H, Fujihira S, Ohara K, Noguchi H, Mine Y: Tacrolimus (FK506)-induced nephrotoxicity in spontaneously hypertensive rats. J Toxicol Sci 19:219-226, 1994.
9. Nielsen FT, Leyssac PP, Kemp E, Starklint H, Dieperink H: Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. Transplantation Proceedings 26:3104-3105, 1994.
10. Nielsen FT, Leyssac PP, Kemp E, Starklint H, Dieperink H: Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. Nephrology, Dialysis, Transplantation 10:334-340, 1995.
11. Bagnis C, Deray G, Dubois M, Adabra Y, Jacquiaud C, Jaudon MC, Jacobs C: Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. Amer J Nephrol 17:17-24, 1997.
12. Mitamura T, Yamada A, Ishida H, Fujihira S, Ohara K, Noguchi H, Mine Y: Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci 19:219-226, 1994.
13. Golbaekdal K, Nielsen CB, Pedersen EB: The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressm in pigs. J Pharm Pharmacol 48(11):1174-1191, 1996.
14. Canzanello VJ, Textor SC, Taler SJ, Wilson DJ, Schwartz L, Wiesner RH, Porayko MK, Krom RA: Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. J Amer Soc Nephrol 5:1910-1917, 1995.
15. Stillman IE, Andoh TF, Burdmann EA, Bennett WM, Rosen S: FKS06 nephrotoxicity: morphologic and physiologic characterization of a rat model. Lab Invest 73:794-803, 1995.
16. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Amer J Surg Pathol 17:60-68, 1993.
17. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM: Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50:1110-1117, 1996.
18. Burdmann EA, Andoh TF, Lindsley J, Russell J, Bennett WM, Porter G: Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Renal Failure 16:161-168, 1994.
19. Katari SR, Magnone M, Shapiro R, Jordan M, Scantlebury V, Vivas C, Gritsch A, McCauley J, Starzl T, Demetris AJ, Randhawa PS: Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clinical Transplantation 11:237-242, 1997.
20. Becker G, Witzke O, Baltes A, Hamar P, Philipp T, Heemann U: Dittiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. Transplant Immunology 4:68-71, 1996.
21. Cacciarelli TV, Sumrani NB, Hong JH, Chen CK, Sommer BG: Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. ASAIO Journal 40:964-967, 1994.
22. Kumano K, Wang G, Endo T, Kuwao S: FK506-induced nephrotoxicity in rats. Transplant Proc 23:512-515, 1992.
23. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr, Gores G, Hay E, Dickson ER, Krom RA: Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 55:1332-1339, 1993.
24. Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Wahlstrom HE, Sanchez-Urdazpal L, Richards T, Crotty P, Beaver S, et al: Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. Transplant. Proc 25:665-668, 1993.
25. Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH: Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clinic Proc 69:105-111, 1994.
26. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, Klintmalm G: Chronic nephrotoxicity of FK 506 after liver transplantation. Transplant Proc 26:1803, 1994.
27. Muraoka K, Fujimoto K, Sun X, Yoshioka K, Shimizu K, Yagi M, Bose H Jr, Miyazaki I, Yamamoto K: Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Invest 97:2433-2439, 1996.
28. Shihab FS, Andoh TF, Tanner A, Bennett WM: Mechanism of fibrosis in experimental chronic tacrolimus nephropathy. J Amer Soc Neph 8:608A, 1997.
29. Shihab FS, Andoh TF, Tanner A, Bennett WM: Mechanism of fibrosis in tacrolimus nehropathy: Expression of TGF-B1 and matreix proteins. Abst Amer Soc Transpl Phy 1997.
30. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 64:1829-1837, 1997.
31. Rump LC, Wehrens J, Schwertfeger E, Krumme B, Schollmeyer P: Effect of tacrolimus and cyclosporine A on rat renal vascular tone. J Amer Soc Neph 8:664A, 1997.
32. Su Q, Weber L, Le Hir M, Zenke G, Ryffel B: Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Renal Physiology & Biochemistry 18:128-39, 1995.
33. Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Cusick PK, Hsieh GC, Luly JR: Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology 125:169-181, 1998.
34. Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Brandt JA, Kawai M, Wagner R, Hsieh GC, Luly JR: Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay. Journal of Pharmacology & Experimental Therapeutics 283:1509-1519, 1997.
35. Andoh TF, Burdman EA, Lindsley J, Bennett WM: Dose-dependent effects of calcium-channel blockade on acute tacrolimus nephrotoxicity. J Amer Soc Neph 8:598A, 1997.
36. Dumont FJ, Staruch MJ, Koprak SL et al. The immunosuppressive and toxic effects of FK-506 and mechanistically related. Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 176/3:751-760, 1992.
37. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui C, Piccinelli A, Donadelli R, Remuzzi G: The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54:775-780, 1992.
38. McCauley J, Studer R, Craven F, Murray S: The effects of cyclosporine A, cyclosporine G, and FK 506 upon prostaglandin production in renal mesangial cells in culture. Transplant Proc 23:3141-3142, 1991.
39. Holtback U, Eklof A-C: FK-induced nephrotoxicity is reversed by β-adrenergic antagonists. J Amer Soc Neph 8:602A, 1997.
40. Uchida J, Miura K, Yamanaka S, Kim S, Iwao H, Nakatani T, Kishimoto T: Renal endothelin in FK506-induced nephrotoxicity in spontaneously hypertensive rats. Japanese Journal of Pharmacology 76:39-49, 1998.
41. Moutabarrik A, Ishlbaahi M, Fukunaga M, Kameoka H, Takano Y, Kokado Y et al. FK506 mechanism of nephrotoxicity:stimulatory effect on endothelein secretion by cultured kidney cells and tubular cell toxicity in vitro. Transplant Proc 23:3133-3136, 1991.
42. Moutabarrik A, Ishlbaahi M, Kameoka H, Ogata A, Kawaguchi N, Takano Y, et al. In vitro FK506 kidney tubular cell toxicity. Transplant Proc 23:3137-3140, 1991.
43. Moutabarrik A, Ishlbaahi M, Fukunaga M, Kameoka H, Takano Y, Kokado Y et al. FK506-induced kidney tubular cell injury. Transplantation 54:1041-1047, 1992.
44. Goodall T, Kind CN, Hammond TG: FK506-induced endothelin release by cultured rat mesangial cells. J Cardiovascular Phramacology 26 (Suppl 3):S482-S485, 1995.
45. Hammond TG, Kind CM: Pancreatic and nephrotoxicity of immunomodulator compounds. Toxicology Letters 82-83:99-105, 1995.
46. Schettler V, Wieland E, Schuff-Wemer HI, Schutz E, Oellerich M, Muller GA: Free radical scavenging enzyme activities in granulocytes from renal transplant recipients under immunosuppressive therapy: Cyclosporine and tacrolimus compared. J Amer Soc Neph 8:703A, 1997.
47. Edkins RD, Rybak LP, Hoffman DW: comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. Biochem Pharmacol 43:911-913, 1992.
48. Aicher L, Meier G, Norcross AJ, Jakubowski J, Varela MC, Cordier A, Steiner S: Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. Biochemical Pharmacology 53:723-731, 1997.